Polycystic ovary syndrome: The new millenium

Molecular and Cellular Endocrinology

Volumn 184, Issue 1-2, 2001, Pages 87-93

  Legro, Richard S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Gonadotropin; Polycystic; Syndrome

Indexed keywords

ANDROGEN; GONADOTROPIN; INSULIN; TESTOSTERONE;

ARTICLE; FEMALE; HUMAN; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; INFERTILITY, FEMALE; POLYCYSTIC OVARY SYNDROME;

EID: 0035955884     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(01)00640-2     Document Type: Article

References (74)

1. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism
2. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial
3. Cumulative conception and live birth rates after the treatment of anovulatory infertility: safety and efficacy of ovulation induction in 200 patients
4. Results of gonadotrophin stimulation with the option to convert cycles to in vitro fertilization in cases of multifollicular development
5. Native gonadotropin-releasing hormone for triggering follicular maturation in polycystic ovary syndrome patients undergoing human menopausal gonadotropin ovulation induction
6. Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertilization
7. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome
8. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome
9. Chronic anovulation syndrome and associated neoplasia
10. A model for prediction of endometrial cancer
11. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones
12. The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome
13. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile
14. Surgically induced ovulation in the polycystic ovary syndrome: wedge resection revisited in the age of laparoscopy
15. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis
16. Insulin-lowering therapeutic modalities for polycystic ovary syndrome
17. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome
18. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing
19. Treatment of anovulatory infertility: the problem of multiple pregnancy
20. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women
21. Polycystic ovary syndrome
22. Prevalence of and etiological factors in polycystic ovarian syndrome
23. The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome
24. Polycystic ovaries and the risk of breast cancer
25. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism
26. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome
27. Clinical and biochemical features of polycystic ovarian disease
28. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study
29. Hirsutism: implications, etiology, and management
30. Objective assessment of treatment response in hirsutism
31. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone
32. Protection against endometrial carcinoma by combination-product oral contraceptives
33. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies
34. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the lipid research clinics prevalence study
35. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome
36. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study
37. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome
38. Polycystic ovary syndrome. Phenotype to genotype
39. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women
40. Hirsutism in polycystic ovary syndrome: current concepts
41. Evidence for the importance of peripheral tissue events in the development of hirsutism in polycystic ovary syndrome
42. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study
43. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
44. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial
45. Insulin regulation of human ovarian androgens
46. Evidence that an altered prolactin release is consequent to abnormal ovarian activity in polycystic ovary syndrome
47. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment
48. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome
49. Mortality of women with polycystic ovary syndrome at long-term follow-up
50. Polycystic ovaries-a common finding in normal women
51. Banting lecture 1988. Role of insulin resistance in human disease
52. Epithelial ovarian cancer risk among women with polycystic ovary syndrome
53. Abnormal production of androgens in women with breast cancer
54. Serum and urinary androgens and risk of breast cancer in postmenopausal women
55. Increased 5 α-reductase activity in idiopathic hirsutism
56. Abnormal menstrual cycle length predicts subsequent diabetes mellitus
57. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study
58. Thirty-seven candidate genes for polycystic ovary sydnrome: strongest evidence for linkage is with follistatin
59. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome
60. Endometrial and ovarian cancer and oral contraceptives-findings in a large cohort study
61. Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA)
62. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization
63. The use of human gonadotropins for the induction of ovulation in women with polycystic ovarian disease
64. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome
65. Use of oral contraceptives and endometrial cancer risk (Sweden)
66. High density lipoprotein cholesterol and mortality. The Framingham heart study
67. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome
68. Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism
69. Ovulation induction with gonadotropin-releasing hormone